{"disease":{"id":"relapsed-and-refractory-acute-leukemia","name":"relapsed and refractory acute leukemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04609241","title":"CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT05445765","title":"Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"iCell Gene Therapeutics","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}